| Literature DB >> 22040231 |
Chih-Hsuan Changchien1, Ying-Ying Chen, Shu-Wun Chen, Wan-Lin Chen, Jwu-Guh Tsay, Chishih Chu.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a prevalent pathogen of necrotizing fasciitis (NF) in Taiwan. A four-year NF cases and clinical and genetic differences between hospital acquired (HA)- and community-acquired (CA)-MRSA infection and isolates were investigated.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22040231 PMCID: PMC3221646 DOI: 10.1186/1471-2334-11-297
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics of 247 NF cases and antimicrobial resistance of CA- and HA-MRSA isolates
| Characteristic | Non- | MSSA | CA-MRSA | HA-MRSA | p-value |
|---|---|---|---|---|---|
| Age (mean, yr)§ | 59.1 ± 13.0 | 56.0 ± 17.9 | 53.8 ± 14.3 | 57.4 ± 15.3 | 0.262 |
| Male (n, %) | 107 (68.6) | 27 (64.3) | 13 (52) | 17 (70.8) | 0.399 |
| Comorbidities (n, %)† | 1.8 (1.2) | 1.9 (1.5) | 1.4 (1.1) | 2.9 (1.5) | <0.001*** |
| Hospitalization (mean, day)§ | 17.2 ± 10.6 | 15 ± 8.6 | 13.2 ± 8.3 | 20.3 ± 8.1 | 0.052 |
| Underlying chronic disease | |||||
| Diabetes mellitus (n, %) | 95 (60.9) | 25 (59.5) | 15 (60.0) | 20 (83.3) | 0.183 |
| Hypertension (n, %) | 59 (37.8) | 17 (40.5) | 7 (28.0) | 11 (45.8) | 0.616 |
| Chronic hepatic disease (n, %) | 19 (12.2) | 8 (19) | 4 (16) | 5 (20.8) | 0.451 |
| Malignancy (n, %) | 6 (3.8) | 2 (4.8) | 0 (0) | 0 (0) | 0.765 |
| Obesity (n, %) | 17 (10.9) | 3 (7.1) | 0 (0) | 1 (4.2) | 0.300 |
| Pulmonary disease (n, %) | 11 (7.1) | 3 (7.1) | 0 (0) | 2 (8.3) | 0.600 |
| Chronic azotemia (n, %) | 26 (16.7) | 6 (14.3) | 2 (8) | 10 (41.7) | 0.019* |
| Operative procedure (mean, n) | 2.1 ± 1.1 | 1.9 ± 0.6 | 2.1 ± 0.9 | 2.4 ± 1.5 | 0.237 |
| Reconstructive surgery (n, %) | 15 (9.6) | 2 (4.8) | 8 (32) | 7 (29.2) | <0.001*** |
| Amputation (n, %) | 18 (11.5) | 2 (4.8) | 2 (8) | 7 (29.2) | 0.037* |
| Mortality (n, %) | 5 (3.2) | 0 (0) | 0 (0) | 1 (4.2) | 0.542 |
| Site of infection | |||||
| Upper extremity (n, %) | 18 (11.5) | 8 (19) | 4 (16) | 1 (4.2) | 0.315 |
| Lower extremity (n, %) | 103 (66) | 25 (59.5) | 17 (68) | 20 (83.3) | 0.005** |
| Head and neck (n, %) | 1 (0.6) | 4 (9.5) | 2 (8) | 1 (4.2) | 0.014* |
| Trunk (n, %) | 34 (21.8) | 5 (11.9) | 2 (8) | 2 (8.3) | 0.118 |
| Body temperature (°C) (mean)§ | 36.9 ± 0.8 | 36.9 ± 0.5 | 36.8 ± 0.5 | 37.1 ± 0.7 | 0.624 |
| Shock (n, %) | 4 (2.6) | 0 (0) | 2 (8) | 1 (4.2) | 0.170 |
| Leukocyte count (mean cells/mm3)§ | 13.9 ± 7.4 | 14.1 ± 5.1 | 12.9 ± 5.5 | 15.1 ± 7.7 | 0.752 |
| Platelet count (mean, per mm3) | 248.3 ± 107.9 | 263.2 ± 96.9 | 290.5 ± 120.2 | 293.9 ± 99.5 | 0.101 |
| C-reactive protein (mean, mg/dl)‡ | 15.8 ± 13.2 | 12.2 ± 11.8 | 10.4 ± 10.6 | 25.5 ± 14.8 | 0.005** |
| Antimicrobials resistance | CA-MRSA | HA-MRSA | |||
| Clindamycin (n, %) | 23 (92.0) | 23 (95.8) | 0.576 | ||
| Erythromycin (n, %) | 23 (92.0) | 23 (95.8) | 0.576 | ||
| Fucidic acid (n, %) | 3 (12.0) | 3 (12.5) | 0.957 | ||
| Trimethoprim-sulfamethoxazole (n, %) | 1 (4.0) | 11 (45.8) | <0.001*** |
§ Data represents as mean ± standard deviation or number of cases (prevalence, %).
† Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.001; MSSA < HA-MRSA, p = 0.02; CA-MRSA < HA-MRSA, p < 0.001.
‡ Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.045; MSSA < HA-MRSA, p = 0.008; CA-MRSA < HA-MRSA, p = 0.007.
* indicates significant differences among four groups (p < 0.05); ** and *** indicates highly significant among four groups with p < 0.01 and p < 0.001 respectively.
The number of microbial species associated with NF
| Organism | Monomicrobial | Polymicrobial | Total (%) | ||||
|---|---|---|---|---|---|---|---|
| Number | A,% | B,% | Number | A,% | B,% | ||
| MRSA | 34 | 30.9 | 13.8 | 15 | 3.9 | 6.1 | 49 (19.8) |
| MSSA | 26 | 23.6 | 10.5 | 16 | 4.2 | 6.5 | 42 (16.6) |
| Coagulase-negative S | 3 | 2.7 | 1.2 | 13 | 3.4 | 5.3 | 16 (6.5) |
| 1 | 0.3 | 0.4 | 1 (0.4) | ||||
| 1 | 0.9 | 0.4 | 18 | 4.7 | 7.3 | 19 (7.7) | |
| Group A | 6 | 5.5 | 2.4 | 9 | 2.4 | 3.6 | 15 (6.1) |
| Group B | 3 | 2.7 | 1.2 | 14 | 3.7 | 5.7 | 17 (6.9) |
| Group G | 6 | 1.6 | 2.4 | 6 (2.4) | |||
| Other | 1 | 0.3 | 0.4 | 1 (0.4) | |||
| 4 | 3.6 | 1.6 | 33 | 8.7 | 13.4 | 37 (15.0) | |
| 4 | 1.1 | 1.6 | 4 (1.6) | ||||
| 2 | 0.5 | 0.8 | 2 (0.8) | ||||
| 10 | 9.1 | 4.0 | 4 | 1.1 | 1.6 | 14 (5.7) | |
| 6 | 5.5 | 2.4 | 26 | 6.8 | 10.5 | 32 (13.0) | |
| 3 | 2.7 | 1.2 | 21 | 5.5 | 8.5 | 24 (9.7) | |
| 2 | 1.8 | 0.8 | 23 | 6.1 | 9.3 | 25 (10.1) | |
| 1 | 0.9 | 0.4 | 15 | 3.9 | 6.1 | 16 (6.5) | |
| 1 | 0.9 | 0.4 | 12 | 3.2 | 4.9 | 13 (5.3) | |
| 1 | 0.9 | 0.4 | 2 | 0.5 | 0.8 | 3 (1.2) | |
| 1 | 0.9 | 0.4 | 1 | 0.3 | 0.4 | 2 (0.8) | |
| 9 | 2.4 | 3.6 | 9 (3.6) | ||||
| 7 | 1.8 | 2.8 | 7 (2.8) | ||||
| 4 | 1.1 | 1.6 | 4 (1.6) | ||||
| 3 | 0.8 | 1.2 | 3 (1.2) | ||||
| 2 | 0.5 | 0.8 | 2 (0.8) | ||||
| 1 | 0.3 | 0.4 | 1 (0.4) | ||||
| 1 | 0.3 | 0.4 | 1 (0.4) | ||||
| 1 | 0.3 | 0.4 | 1 (0.4) | ||||
| 3 | 2.7 | 1.2 | 29 | 7.6 | 11.7 | 32 (13.0) | |
| 2 | 1.8 | 0.8 | 35 | 9.2 | 14.2 | 37 (15.0) | |
| 1 | 0.9 | 0.4 | 31 | 8.2 | 12.6 | 32 (13.0) | |
| 1 | 0.9 | 0.4 | 9 | 2.4 | 3.6 | 10 (4.0) | |
| 8 | 2.1 | 3.2 | 8 (3.2) | ||||
| 2 | 0.5 | 0.8 | 2 (0.8) | ||||
| 1 | 0.3 | 0.4 | 1 (0.4) | ||||
| 1 | 0.9 | 0.4 | 1 | 0.3 | 0.4 | 2 (0.8) | |
| 110 | 100 | 44.5 | 380 | 100 | 55.5 | 247 (100) | |
*:A = [Number of isolate of the microbial species/Total number of monomicrobial (110) or polymicrobial (380)] × 100%
B = (Number of isolation/247) × 100%
Figure 1Prevalence of MRSA and MSSA associated with 247 NF cases in 2005 to 2008.
Characteristics of 16 CA- and HA-MRSA and their clinical association
| Isolate | ST | Allelic profile | PFGE | Pulsotype* | Antibiogram | SCC | CA/HA | Virulence | Clinical | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| genotype | CC | CIP | ERY | FA | GM | KM | SXT | TE | type | MRSA | factor | association | ||||||||||
| SA141 | 9 | 3 | 3 | 1 | 1 | 1 | 1 | 10 | gt-7 | ND1 | R | R | R | S | R | R | S | R | V | HA | Hlg | Healed |
| SA93 | 30 | 2 | 2 | 2 | 2 | 6 | 3 | 2 | gt-8 | ND2 | R | I | R | S | R | R | S | S | IV | CA | Hlg | Bacteremia |
| SA49 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-2a | C | R | I | R | S | R | R | S | S | IV | HA | Hlg, ETA | Amputation |
| SA52 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-2b | C | R | I | R | S | R | R | S | R | IV | CA | Hlg, TSST | Healed |
| SA104 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-2c | C | R | I | R | S | I | I | S | S | IV | HA | Hlg | Healed |
| SA46 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-2d | C | R | I | R | S | I | R | S | S | IV | CA | Hlg, ETA | Amputation |
| SA10 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-2e | C | R | I | R | S | I | R | S | R | IV | HA | Hlg | Healed |
| SA215 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-3 | D | R | I | R | S | I | R | S | S | V | HA | Hlg, PVL | Skin graft |
| SA100 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-4 | D | R | I | R | S | I | R | R | R | IV | HA | Hlg | Bacteremia, |
| SA123 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-5a | D | R | I | R | S | I | R | S | R | VII | CA | Hlg, PVL | Healed |
| SA156 | 59 | 19 | 23 | 15 | 2 | 19 | 20 | 15 | gt-5b | D | R | I | R | S | I | R | S | S | V | CA | Hlg, PVL | Skin graft |
| SA19 | 239 | 2 | 3 | 1 | 1 | 4 | 4 | 3 | gt-1a | A | R | R | R | R | R | R | R | R | III | HA | Hlg | Amputation |
| SA31 | 239 | 2 | 3 | 1 | 1 | 4 | 4 | 3 | gt-1b | A | R | R | R | S | R | R | R | R | III | HA | Hlg | Bacteremia |
| SA151 | 239 | 2 | 3 | 1 | 1 | 4 | 4 | 3 | gt-1c | A | R | R | R | S | R | R | S | R | III | HA | Hlg | Amputation |
| SA167 | 238 & | 2 | 1a | 1 | 1 | 4 | 4 | 1b | gt-1c | A | R | R | R | S | R | R | S | R | III | HA | Hlg | Bacteremia, amputation |
| SA165 | 1279 like | 1 | 3c | 1 | 1 | 12 | 1 | 3 | gt-6 | O | R | I | R | S | R | R | S | R | Non-type | HA | Hlg | Bacteremia |
* ND means that pulsotype could not be determined and pulsotypes were similar to those reported in Huang et al. [7].
Figure 2PFGE patterns of . M: lambda DNA. ND1 and ND2 mean new pulsotypes.